Sun Pharmaceutical Industries Limited (IN:SUNPHARMA)
:SUNPHARMA
Top Page
Sun Pharmaceutical Industries Limited
(SUNPHARMA)
Select Model
Select Model
Rating:73Outperform
Price Target:
₹1,778.00
▲(2.77% Upside)
Action:UpgradedDate:11/28/25
Sun Pharmaceutical Industries Limited's overall stock score is driven by its strong financial performance, characterized by robust profitability and effective cost management. Technical analysis shows bullish momentum, although overbought signals suggest caution. The valuation indicates potential overvaluation, which slightly offsets the positive financial outlook.
Positive Factors
Low Leverage / Strong Balance Sheet
A very low debt-to-equity ratio provides durable financial flexibility to fund R&D, capital spending, acquisitions, or weather pricing cycles without stressing liquidity. This structural strength reduces refinancing risk and supports multi-quarter investment in specialty and complex portfolios.
Negative Factors
Negative EPS Growth
Declining EPS despite revenue gains points to margin dilution, higher costs, or non-operating impacts that depress per‑share earnings. Persisting EPS weakness can limit per-share returns, reduce flexibility for buybacks/dividends, and signal operational or capital allocation issues over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
A very low debt-to-equity ratio provides durable financial flexibility to fund R&D, capital spending, acquisitions, or weather pricing cycles without stressing liquidity. This structural strength reduces refinancing risk and supports multi-quarter investment in specialty and complex portfolios.
Read all positive factors
Sun Pharmaceutical Industries Limited (SUNPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹4.31T
Dividend Yield0.91%
Average Volume (3M)102.58K
Price to Earnings (P/E)30.6
Beta (1Y)0.62
Revenue Growth9.26%
EPS Growth-5.47%
CountryIN
Employees43,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)14.70
Shares Outstanding2,399,278,300
10 Day Avg. Volume56,056
30 Day Avg. Volume102,581
Financial Highlights & Ratios
PEG Ratio2.61
Price to Book (P/B)5.64
Price to Sales (P/S)7.74
P/FCF Ratio34.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,916.33Price Target Upside10.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)49.98
Revenue Forecast (FY)₹581.46B
Sun Pharmaceutical Industries Limited Business Overview & Revenue Model
Company Description
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulation...
How the Company Makes Money
Sun Pharmaceutical Industries Limited generates revenue primarily through the sale of its pharmaceutical products, which includes branded medications, generic drugs, and specialty products. The company has a robust revenue model that is supported ...
Sun Pharmaceutical Industries Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
80
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 549.64B | 525.78B | 484.97B | 438.86B | 386.54B | 334.98B |
| Gross Profit | 359.81B | 410.20B | 370.55B | 325.67B | 277.78B | 242.80B |
| EBITDA | 165.42B | 149.68B | 128.76B | 116.51B | 101.54B | 83.45B |
| Net Income | 104.50B | 109.29B | 95.76B | 84.74B | 32.73B | 29.04B |
Balance Sheet | ||||||
| Total Assets | 1.04T | 921.01B | 854.63B | 807.44B | 698.00B | 676.67B |
| Cash, Cash Equivalents and Short-Term Investments | 278.80B | 249.88B | 190.90B | 159.07B | 126.55B | 95.63B |
| Total Debt | 52.15B | 23.62B | 32.74B | 68.90B | 12.90B | 38.69B |
| Total Liabilities | 255.80B | 196.15B | 183.57B | 214.28B | 187.34B | 181.87B |
| Stockholders Equity | 778.20B | 722.18B | 636.67B | 559.95B | 480.11B | 464.63B |
Cash Flow | ||||||
| Free Cash Flow | 23.93B | 119.44B | 99.33B | 28.74B | 74.89B | 50.00B |
| Operating Cash Flow | 47.81B | 140.72B | 121.35B | 49.59B | 89.85B | 61.70B |
| Investing Cash Flow | -66.91B | -53.06B | -6.90B | -79.44B | -57.25B | 5.36B |
| Financing Cash Flow | 11.01B | -79.06B | -67.10B | 23.76B | -51.93B | -59.80B |
Sun Pharmaceutical Industries Limited Technical Analysis
Positive
1730.15
Price Trends
1719.35
Positive
1733.20
Positive
1686.66
Positive
Market Momentum
13.24
Positive
56.87
Neutral
48.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SUNPHARMA, the sentiment is Positive. The current price of 1730.15 is below the 20-day moving average (MA) of 1782.80, above the 50-day MA of 1719.35, and above the 200-day MA of 1686.66, indicating a bullish trend. The MACD of 13.24 indicates Positive momentum. The RSI at 56.87 is Neutral, neither overbought nor oversold. The STOCH value of 48.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SUNPHARMA.
Sun Pharmaceutical Industries Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹1.59T | 72.71 | ― | 0.46% | 16.43% | 35.35% | |
73 Outperform | ₹4.31T | 30.62 | ― | 0.91% | 9.26% | -5.47% | |
72 Outperform | ₹1.07T | 20.49 | ― | 0.57% | 15.49% | 64.37% | |
70 Outperform | ₹1.07T | 21.88 | ― | 0.63% | 14.10% | 9.72% | |
68 Neutral | ₹1.00T | 45.14 | ― | 0.87% | 6.93% | 21.55% | |
66 Neutral | ₹1.44T | 51.30 | ― | 0.84% | 9.11% | 18.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,795.65
77.06
4.48%
IN:CIPLA
Cipla Ltd
1,242.65
-186.62
-13.06%
IN:DIVISLAB
Divi's Laboratories Limited
5,996.00
472.65
8.56%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,281.95
136.81
11.95%
IN:LUPIN
Lupin Limited
2,334.95
390.63
20.09%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
4,266.40
1,059.91
33.06%
Sun Pharmaceutical Industries Limited Corporate Events
Sun Pharma Publishes Q3 FY26 Unaudited Results Notice in Newspapers
Feb 1, 2026
Sun Pharmaceutical Industries Limited has notified the stock exchanges that it has published newspaper advertisements in the Financial Express (all editions) and the Vadodara edition of Loksatta Jansatta, providing information on its unaudited fin...
Sun Pharma Rolls Out UNLOXCYT in U.S. for Advanced Skin Cancer Patients
Jan 15, 2026
Sun Pharmaceutical Industries has launched UNLOXCYT (cosibelimab-ipdl) in the U.S. for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, strengthening its presenc...
Sun Pharma’s Baska Facility Receives OAI Classification from US FDA
Dec 18, 2025
Sun Pharmaceutical Industries Limited announced that the US FDA has classified their Baska facility inspection status as Official Action Indicated (OAI) following an inspection conducted in September 2025. Despite the OAI classification, the compa...
Sun Pharma to Invest INR 3,000 Crores in New Manufacturing Facility
Dec 2, 2025
Sun Pharmaceutical Industries Limited announced that its wholly-owned subsidiary, Sun Pharma Laboratories Limited, has approved a significant investment of INR 3,000 crores to establish a new greenfield formulations manufacturing facility in Madhy...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.